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In Brief
Cholesterol is a prerequisite for growth of
cancer cells. Gabitova et al. show that
blockade of cholesterol biosynthesis at
the C4-demethylation step results in
suppression of tumor growth. Cholesterol
blockade leads to the accumulation of
sterol metabolites that activate nuclear
receptor LXRa and its transcriptional
targets, leading to an uncompensated
loss of cholesterol.
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Meiosis-activating sterols (MAS) are substrates of
SC4MOL and NSDHL in the cholesterol pathway
and are important for normal organismal develop-
ment. Oncogenic transformation by epidermal
growth factor receptor (EGFR) or RAS increases the
demand for cholesterol, suggesting a possibility for
metabolic interference. To test this idea in vivo, we
ablated Nsdhl in adult keratinocytes expressing
KRASG12D. Strikingly,Nsdhl inactivation antagonized
the growth of skin tumors while having little effect on
normal skin. Loss of Nsdhl induced the expression of
ATP-binding cassette (ABC) transporters ABCA1 and
ABCG1, reduced the expression of low-density lipo-
protein receptor (LDLR), decreased intracellular
cholesterol, and was dependent on the liver X recep-
tor (LXR) a. Importantly, EGFR signaling opposed
LXRa effects on cholesterol homeostasis, whereas
an EGFR inhibitor synergized with LXRa agonists in
killing cancer cells. Inhibition of SC4MOL or NSDHL,
or activation of LXRa by sterol metabolites, can be an
effective strategy against carcinomas with activated
EGFR-KRAS signaling.
INTRODUCTION
Oncogene-transformed cancer cells require elevated levels of
cholesterol to support their rapid growth. In addition to enhanced
de novo cholesterol synthesis (Pitroda et al., 2009; Silvente-
Poirot and Poirot, 2014), the process of cholesterol uptake is
also tightly regulated by the signaling activity of the epidermal
growth factor receptor (EGFR) and increased in cancer (Guo
et al., 2011). The cholesterol metabolic pathway proceeds
through a series of elongation reactions from mevalonate to anCell Repisoprenoid, squalene. Subsequent cyclization of the squalene
carbon chains produces the first sterol precursor, lanosterol,
which is further metabolized through a series of oxygen-depen-
dent reactions to produce the final product, cholesterol. The role
of the isoprenoid precursors in protein prenylation (Clendening
et al., 2010a) or of cholesterol in formation of lipid rafts that sup-
port oncogenic signaling platforms (Munro, 2003) is well-estab-
lished. In contrast, relatively little is known about the biological
activities of the intermediate sterol metabolites.
Central in the sterol synthesis pathway producing metabo-
lites essential to convert squalene to cholesterol, SC4MOL
and NSDHL (Nes, 2011) catalyze two sequential steps of oxida-
tive decarboxylation of the C4 methyl groups from meiosis-acti-
vating sterols (MAS) (Acimovic and Rozman, 2013). Mutations
in SC4MOL or NSDHL lead to significant accumulation of
testicular tissue MAS (T-MAS) and follicular fluid MAS (FF-
MAS) (He et al., 2011; Liu et al., 1999). Under physiological
conditions, these MAS are abundant in male and female go-
nads and regulate meiosis (Byskov et al., 1995) through a
mechanism that involves release of EGFR ligands and activated
receptor signaling (Park et al., 2004). In previous work, we had
pursued suggestions from an RNAi-based sensitization screen
to establish that depletion of SC4MOL and NSDHL, but not
enzymes operating upstream or downstream in the sterol syn-
thesis pathway, sensitized cancer cells to the EGFR inhibitors
cetuximab and erlotinib (Sukhanova et al., 2013). These
EGFR-inhibitor-sensitizing effects of SC4MOL and NSDHL
were mediated by the MAS sterol metabolites and were
observed both in vitro and in xenograft analysis in vivo (Sukha-
nova et al., 2013), suggesting further study of SC4MOL,
NSDHL, and MAS might be informative in cancers dependent
on EGFR pathway signaling.
The cellular targets and the effector mechanisms for MAS
have remained unclear for some time. However, one in vitro
study using luciferase reporter assays in CV-1 cells suggested
an important target of MAS may be the sterol-binding transcrip-
tion factor, liver X nuclear receptor (LXR) (Janowski et al., 1996),orts 12, 1927–1938, September 22, 2015 ª2015 The Authors 1927
Figure 1. Blockade of Keratinocyte Prolifer-
ation by Conditional Inactivation of NSDHL
(A) Survival of K14Cre;NsdhlD5/+ females and
K14Cre;NsdhlD5/Y males. Shown are pooled data
from three independent crosses; *p = 104.
(B) Conditional inactivation of Nsdhl produces
hyperkeratotic, scaly patches, and a striped coat
in 1-week-old heterozygous K14Cre;NsdhlD5/+
female pups.
(C) NSDHL-deficient areas of the dorsal skin in 4-
week-old K14Cre;NsdhlD5/+ females show
reduced thickness and proliferation of the basal
layer keratinocytes (Ki67-positive nuclei). See also
Figure S3.
(D) Delayed hair regrowth (dashed line) following
conditional Nsdhl ablation in the skin of adult
K5CreERT;Nsdhlflx5/Y mice following oral admin-
istration of vehicle (left, corn oil) or tamoxifen
(right, 40 mg/kg) for 5 consecutive days at
age of 12 weeks. One week after treatment,
the coat from the dorsal skin was depilated
and hair regrowth was imaged 1 week after
depilation.
(E) No change in interfollicular epidermis Ki67-positive cells or epidermis thickness in tamoxifen-treated adult K5CreERT;Nsdhlflx5/Y mice. See also Figure S4.
Digital imaging data are presented as mean ± SEM. p values: (1) p = 3 3 106; (2) p = 3 3 1016; (3) p = 2 3 105; (4) p = 2 3 1016, based on Wilcoxon test.which plays a critical role in regulating de novo synthesis and up-
take of cholesterol (Zelcer et al., 2009). LXR, as a heterodimer
with retinoid X receptor (RXR), is a transcription factor activated
by specific oxysterol metabolites to induce the expression of
multiple targets including ABCG1 and ABCA1, cholesterol efflux
pumps associated with the ER vesicles and the cell-surface
membrane, respectively (Venkateswaran et al., 2000). Activation
of LXR also reduces cholesterol uptake by promoting the ubiqui-
tin-dependent degradation of low-density lipoprotein receptor
(LDLR) and, intriguingly, is cytotoxic to cancer cells with hyper-
active EGFR signaling (Guo et al., 2011) and antagonizes angio-
genesis and metastatic spread (Pencheva et al., 2014).
Nsdhl was first identified as the gene associated with the
X-linked dominant, male lethal mouse mutations bare patches
(Bpa) and striated (Str). Heterozygous Bpa/+ female mice are
dwarfed compared to wild-type female littermates (Liu et al.,
1999) and develop hyperkeratotic skin eruptions on postnatal
days 5–7 that resolve leaving a striped coat that follows lines
of X inactivation (Liu et al., 1999). Affected male embryos for all
murine Nsdhl alleles die by midgestation (Caldas et al., 2005).
Heterozygous germline mutations in the human NSDHL gene
cause congenital hemidysplasia and skin ichthyosiform nevi
with limb deformation (CHILD syndrome) (Hummel et al., 2003).
Together, these severe phenotypes raised concerns about the
therapeutic potential of targeting MAS but left open the question
of whether effects would be observed targeting MAS in the adult
setting.
To further evaluate whether inhibition of NSDHL is a potential
therapeutic route in cancer and to assess the toxicity, selectivity,
and mechanism of action of such an approach, we have used
here a recently developed, conditional Nsdhl knockout mouse
model (Cunningham et al., 2015) in the setting of tumor develop-
ment driven by EGFR and its effector, KRAS. The results of this
work have delineated a critical MAS-sensing mechanism medi-
ated by LXR by which tumor cell growth is dependent on endog-1928 Cell Reports 12, 1927–1938, September 22, 2015 ª2015 The Aenous sterol metabolism and support the further exploration of
these enzymes and sterol metabolites as clinical targets.
RESULTS
NSDHL Deficiency Is Tolerated in Adult Animals
Given the known serious consequences of loss of Nsdhl during
embryonic development (Caldas et al., 2005), we first investi-
gated whether more limited loss of the gene could be tolerated
in post-natal or adult animals. For this purpose, we used recently
generated mice with a ‘‘floxed’’ exon 5 conditional knockout
allele ofNsdhlflx5 (Cunningham et al., 2015) crossed to transgenic
animals carrying Cre recombinase gene under the control of the
keratin 14 promoter (K14Cre), which inactivates Nsdhl (denoted
as NsdhlD5) selectively in skin keratinocytes, beginning at
embryonic day 14 (E14) (Wang et al., 1997) (Figure S1). Although
Nsdhl is X linked, this approach yielded viable progenies at term
with an 1:1 male to female ratio, suggesting no embryonic
lethality in hemizygous K14Cre;NsdhlD5/Y males. Male and
female mice appeared fully developed at birth, and pups were
able to crawl and feed; however, all K14Cre;NsdhlD5/Y males
with total NSDHL inactivation in the skin died within 24 hr after
birth with features of dehydration (Figure 1A). Heterozygous X
chromosome mosaic for Nsdhl loss, K14Cre;NsdhlD5/+ female
mice were viable but had impaired hair development at 1 week
of age (Figure 1B), similar to the original Bpa phenotype (Liu
et al., 1999). Evaluation of the NSDHL null areas of 4-week-old
K14Cre;NsdhlD5/+ females showed reduced skin thickness
and fewer Ki67-positive proliferating basal layer keratinocytes
(Figures 1C and S2A–S2C).
As an alternative approach, we generated mice in which
expression of the floxed allele of Nsdhlflx5 was excised in the
keratinocytes of adult animals (Figure S1A) by tamoxifen-acti-
vated CreERT under the control of the murine keratin 5 (K5) pro-
moter (5 days at 12 weeks of age immediately followed by hairuthors
removal; Kim et al., 2009b). In this model, inactivation of Nsdhl
gene in the skin of Nsdhlflx5/Y adult males and Nsdhlflx5/flx5
females delayed the hair regrowth normally expected after
2 weeks after depilation and was the only apparent phenotypic
change (Figure 1D), with no apparent skin toxicity. Histological
analysis of skin from 14-week-old mice with conditional
CreERT-inactivation of NSDHL following tamoxifen treatment
did not affect the number of Ki67-positive cells or the thickness
of interfollicular epidermis in contrast to the K14-Cre;Nsdhlflx5
mice (Figures 1E and S3A). The more subtle phenotype associ-
ated with loss of NSDHL in adults versus newborn animals
suggested that therapeutic targeting of NSDHL and its effectors
may be a viable strategy.
NSDHL Is Critical for De Novo Growth of KRAS-
Transformed Tumors
Next, we tested the effects of conditional Nsdhl ablation in the
skin on tumor development induced by oncogenic KRASG12D
(Jackson et al., 2001; Tuveson et al., 2004). We created mice
carrying three modified genes: the K5CreERTand LSL-KrasG12D
transgenes and the conditional Nsdhlflx5 allele (Experimental
Procedures; Figure S1). In these animals, the LSL-KrasG12D
and Nsdhlflx5 alleles are rearranged after the mice are treated
with tamoxifen at 4 weeks of age, which induces the nuclear
translocation of CreERT protein (Kim et al., 2009a). Cre-medi-
ated rearrangement of the LSL-KrasG12D allele produced
Lox-KrasG12D (Figures S1E and S1F), while rearrangement of
the Nsdhlflx5 allele resulted in loss of NSDHL expression in the
skin and the tumors (Figure S1G).
Prior to the overt appearance of tumors, the Cre-activated
KrasG12D transgene caused hypertrophy of the sebaceous
glands in the dermal layer of the skin and increased thickness
of the interfollicular epidermis (Figures 2A and 2B). These effects
were counteracted by concomitant inactivation of NSDHL in
Nsdhlflx5/Y mice compared to the control age-matched Nsdhl+/+
and were mosaic in Nsdhlflx5/+ animals (Figures 2A and 2B).
Importantly, loss of NSDHL significantly influenced KrasG12D-
dependent tumor growth. Skin tumors appeared at similar
rate in Nsdhlflx5/Y and Nsdhlflx5/+ animals (in 93% and 97% of an-
imals following tamoxifen treatment, respectively). However, the
NSDHL null tumors formed on the Nsdhlflx5/Y background re-
mained small (Figures 2C–2E). In contrast, all KrasG12D-induced
Nsdhl+/+ tumors (Figures 2D–2F) and some (13 of 100) of the
tumors in heterozygous mice (Nsdhlflx5/+; Figures 2C–2E) grew
rapidly. The NSDHL null skin tumors inNsdhlflx5/Ymice appeared
as desiccated papilloma with narrow stem in contrast to broad-
based and fleshy Nsdhl+/+ and some of Nsdhlflx5/+ tumors (Fig-
ure 2E). Parallel western analysis of NSDHL expression in the tu-
mors (Figures 2F and 2G) indicated essentially complete ablation
of NSDHL in the tumors ofNsdhlflx5/Ymice, complete retention in
Nsdhl+/+ tumors, and variable expression in Nsdhlflx5/+ tumors
(Figure 2G). NSDHL has been reported to influence immune
cell maturation, raising the possibility of a non-cell-autonomous
action in promoting through tumor growth through influencing
microenvironment (Santori et al., 2015; Villablanca et al., 2010).
However, we did not detect significant differences in infiltration
by inflammatory cells (Figure S3B) including CD3 T cells (Fig-
ure S3C) between NSDHL-sufficient versus NSDHL-deficientCell Repskin tumors, suggesting the growth impediment was unlikely to
be immune mediated.
To confirm the cell-intrinsic nature of Nsdhl loss on KrasG12D-
dependent tumor growth, we derived mouse embryonic
fibroblasts (MEFs) from embryos carrying the LSL-KrasG12D
transgene with or without a ‘‘floxed’’ allele of Nsdhlflx5 (Jackson
et al., 2001) (Figure S1). At passage 1, these MEF cells were
treated with Cre-adenovirus to activate KrasG12D transgene
expression or with a control GFP-expressing adenovirus (Figures
2H and 2I). The cells were propagated in vitro in media supple-
mented with 10% fetal bovine serum (FBS) and counted at
each passage. Cells carrying the Cre-activated oncogenic
KrasG12D transgene (Tuveson et al., 2004) showed exponential
proliferation compared to the control-treated LSL-KrasG12D cells
(Figure 2H). Notably, Cre-mediated inactivation ofNsdhl (DNsdhl
cells) in three independent MEF lines completely abrogated
the proliferative effect of oncogenic KrasG12D. The DNsdhl or
activated Kras/DNsdhl cells could not be passaged beyond
passage 10 and underwent rapid senescence as assessed
by SA-b-galactosidase positivity, while the KRAS-activated
cells escaped senescence for at least 14 passages (Figures 2I
and S4).
Loss of NSDHL Activates LXR In Vivo
To determinewhether NSDHL deficiency activates LXR signaling
in vivo, we investigated the expression of two critical LXR target
proteins, ABCA1 and LDLR (Bensinger et al., 2008; Guo et al.,
2011; Zelcer et al., 2009). Skin biopsy specimens and skin tissue
lysates obtained from the newborn K14Cre;NsdhD5/Y male pups
show striking induction of ABCA1 protein and mRNA in compar-
ison to NSDHL-positive skins (Nsdhlflx5/flx5 in Figures 3A and 3B).
LDLR has been shown to be degraded following activation of
LXR (Zelcer et al., 2009). In keeping with the increased LXR ac-
tivity, NsdhlD5/Y keratinocytes showed reduced expression of
LDLR (Figures 3C and 3D). Induction of the cholesterol efflux
pump ABCA1 and inhibition of LDLR activity are associated
with cholesterol depletion from the intracellular membranes
(Radhakrishnan et al., 2008) and lead to compensatory cleav-
age-based activation and nuclear translocation of sterol regula-
tory element-binding protein 2 (SREBP2), which positively regu-
lates genes involved in cholesterol synthesis (Hua et al., 1993).
NSDHL-deficient keratinocytes show accelerated proteolytic
conversion of SREBP2 to an active nuclear form in comparison
to Nsdhlflx5/flx5 controls (Figure 3A). Serial analyses of skin sec-
tions from the mosaic K14Cre;NsdhlD5/+ females (4 weeks old)
revealed an expected patchy staining for NSDHL (Figures 3E
and S2). The NSDHL-negative areas were consistently thinner,
had fewer Ki67-expressing keratinocytes, and showedmarkedly
reduced LDLR and increased ABCA1 staining. Together, these
data support LXR activation in NSDHL deficiency in vivo.
Induction of LXR Targets in NSDHL- and
SC4MOL-Deficient Cancer Cells
For potential therapeutic exploitation of the LXR signaling, the
MAS/LXR relationship outlined above would ideally be consis-
tent in multiple tumor models. We evaluated two additional
models. Using a series of SCC61 carcinoma cells in which the
expression of NSDHL or SC4MOL was silenced with specificorts 12, 1927–1938, September 22, 2015 ª2015 The Authors 1929
Figure 2. NSDHL Deficiency Antagonizes the Growth of KRASG12D-Induced Skin Tumors
(A) H&E-stained sections of the skin 4weeks after tamoxifen treatment inducesK5CreERT;LSL-KrasG12D transgenic animals on indicatedNsdhl backgrounds; 203
magnification.
(B) Conditional ablation of Nsdhl antagonized KRASG12D-induced hyperplasia of skin sebaceous glands and interfollicular epidermis. Digital imaging data are
shown as mean ± SEM percent of dermis area and skin thickness from randomly selected skin sections of four animals per group.
(C and D) Tumor volumes (C) and individual tumor growth curves (D) in tamoxifen-induced K5CreERT;LSL-KrasG12D littermates on indicated Nsdhl backgrounds.
Pooled data from n = 3 independent littermates. Error bars, min to max whiskers.
(E) Photographs of skin tumors in the littermates.
(F andG) Loss of NSDHL expression (F) was confirmed bywestern blot (G) of tumor tissue lysates. Pooled data from n = 3 independent littermates. Error bars, min
to max whiskers.
(H) Loss of NSDHL abolishes the proliferative effect of activated KrasG12D in pre-senescent mouse embryonic fibroblasts.
(I) Growth arrest of NSDHL-deficient fibroblasts was associated with accelerated senescence as assessed by SA-b-galactosidase positivity.
See also Figure S5. Data are presented as mean ± SEM. p values: (1) p = 0.03; (2) p = 63 1010; (3) p = 63 104; (4) p = 105; (5) p = 53 104; (6) p = 93 105,
Wilcoxon test.
1930 Cell Reports 12, 1927–1938, September 22, 2015 ª2015 The Authors
Figure 3. Conditional Inactivation of Nsdhl in Skin Keratinocytes Activates LXR
(A) NSDHL, ABCA1, and nuclear SREBP2 protein levels on western blots in skin tissue lysates of newborn mice.
(B) Increased expression of ABCA1 mRNA in the skin of NsdhlD5/Y mice. Data are presented as mean ± SEM from six individual animals. (1) p = 0.01.
(C) LDLR and ABCA1 immunohistochemistry in the newborn skin; 43 magnification.
(D and E) Expression of LDLR and ABCA1 in the interfollicular epidermis of newborn mice (D) and in 4-week-old K14Cre;NsdhlD5/+ mosaic females (E). Digital
imaging data are presented as mean ± SEM of randomly selected tissue sections from three skin samples per group; *p < 0.01; **p < 109, Wilcoxon test.small hairpin RNAs (shRNAs) versus vector controls (Sukhanova
et al., 2013), we found depletion of these proteins increased
levels of cleaved SREBP2 (Radhakrishnan et al., 2008) and
expression of ABCA1 (Figure 4A). The induction of cleaved
SREBP2 was particularly pronounced in lipid-depleted serum
(LDS)media (Figure 4A), which is known to increaseMASmetab-
olite production in NSDHL deficiency (Caldas et al., 2005; Cun-
ningham et al., 2015). ThemRNA encoding ABCA1 and a second
LXR-regulated transporter, ABCG1, were similarly elevated by
depletion of SC4MOL and NSDHL in A431 cervical carcinoma
cells (Figure 4B), while LDLR expression was decreased (Fig-
ure 4C). Silencing of CYP51A1, an enzyme acting upstream of
NSDHL in the cholesterol synthesis pathway that prevents accu-
mulation of MAS (Sukhanova et al., 2013), reversed the upregu-
lation of ABCA1 in NSDHL-deficient cancer cells (Figure 4D),
supporting the idea that upregulation of MAS metabolites is
important in triggering LXR activation. Importantly, the SC4MOL
or NSDHL deficiency caused reduction of total cholesterol in tu-
mor cells (Figure 4E).
We also investigated the expression of ABCA1 and LDLR pro-
teins in pre-senescent (passage 6) MEFs obtained from NSDHL-
deficient bare patches (Bpa1H) mice (Experimental Procedures;
Cunningham et al., 2005). As with cancer cell lines, these
Bpa1H fibroblasts demonstrated high expression of ABCA1 pro-
tein (Figure 4F) and mRNA (Figure 4G) relative to control MEFs,
particularly in the lipid-poor media. The levels of LDLR wereCell Repmarkedly diminished in Bpa1H cells (Figure 4F). Activity of an
LXR-responsive luciferase reporter was significantly elevated
in Bpa1H fibroblasts (Figure 4H).
Human cells express two homologous LXR proteins (Ben-
singer et al., 2008). The LXRa isoform has been shown to be
abundant in the liver and adipose tissue (Peet et al., 1998), while
LXRb is more ubiquitously expressed (Bensinger et al., 2008). In
A431 carcinoma cells, depletion of LXRa, but not LXRb, abro-
gated the ABCA1 induction associated with NSDHL deficiency
(Figures 4I and S5A). Conversely, overexpression of LXRa in
SCC61 cells markedly sensitized these carcinoma cells to the
growth suppression with FF-MAS or another established LXR
ligand, 22(R)-hydroxycholesterol (Figure 4J). Treatment of
LXRb-overexpressing SCC61 cells either with 22(R)-hydroxy-
cholesterol or FF-MAS had no effect on the viability in compari-
son to the control GFP-expressing cells (Figure 4J), indicating
that in the context of squamous epithelial carcinoma cells, the
tested LXR agonists act specifically via LXRa. Together, these
results indicate NSDHL to LXR signaling is a consistent feature
in both normal and cancer cell models with a selective growth-in-
hibiting effect against tumors rather than normal cells in vivo.
Accumulation of Sterol Metabolites in NSDHL-Deficient
Neonatal Skin
The effector mechanism of LXR transcriptional activation in
the NSDHL deficiency is poorly understood. The limited dataorts 12, 1927–1938, September 22, 2015 ª2015 The Authors 1931
Figure 4. Deficiency of MAS Metabolizing Enzymes Activates LXR Targets in Cancer Cells
(A) Increased nuclear (N) fragments of SREBP2 and membrane-bound ABCA1 expression in SCC61 cells with shRNA-silenced SC4MOL (SC4) and NSDHL (N).
(B) qRT-PCR measurement of LXR targets, ABCA1 and ABCG1, in SC4MOL-depleted A431 cells. Results represent mean ± SEM from two independent RNA
samples each analyzed in duplicates.
(C) Expression of ABCA1 and loss of LDLR in NSDHL-silenced A431 cells by western blot.
(D) Silencing of an upstream enzyme, CYP51A1, with siRNA abrogates ABCA1 expression and rescues LDLR in NSDHL-deficient A431 cells (numbers,
normalized bands density).
(E) Reduced total cholesterol levels in SCC61 cells depleted of SC4MOL or NSDHL with shRNA. Data were normalized to total protein and shControl-depleted
cells and represented as mean ± SD of three independent experiments; (1) and (2), p = 0.02 by Kruskal-Wallis test.
(F) Pre-senescent mouse embryonic fibroblasts deficient in NSDHL (Bpa) show increased ABCA1 and loss of LDLR expression. This phenotype is exacerbated in
cholesterol poor conditions which are used to accelerate the metabolic activity in the cholesterol pathway downstream of SREBP2 (LDS, lipid depleted serum;
comp, compactin; HPC, hydroxypropyl-cyclodextrin).
(G and H) IncreasedmRNA of LXR targets, ABCA1 (G), and activity of LXR-luciferase reporter (H) in pre-senescentBpa fibroblasts. Data are presented asmean ±
SEM (n = 2 for G and n = 3 for H); (3) p = 0.03.
(I) siRNA silencing of LXRa, but not LXRb, abrogates ABCA1 expression in NSDHL-deficient A431 cells.
(J) Lentiviral expression of LXRa but not LXRb sensitizes SCC61 cells to FF-MAS and 22(R)-hydroxycholesterol. Shown is the viability of SCC61 cells cultured in
1% LDS with indicated concentrations of sterols for 72 hr. Data are presented as mean ± SEM from four experiments; (4) and (5), p = 0.002. Insert shows
expression of LXRa and LXRb as confirmed by western blot.
1932 Cell Reports 12, 1927–1938, September 22, 2015 ª2015 The Authors
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Cell Repsuggest that T-MAS (Janowski et al., 1996) can modulate LXR-
responsive genes, although no direct interaction of MAS sterols
with LXR has been demonstrated. We found that in vitro treat-
ment of A431 cells with several distinct LXR agonists, 22(R)-
hydroxycholesterol, GW3965, or FF-MAS produced different
effects on LXR targets (Figure S5B), and it is also possible that
additional, as yet unidentified metabolites accumulating in
NSDHL null cells also contribute to LXR activation. We therefore
conducted detailed gas chromatography-mass spectrometry
(GC-MS) analysis of sterol metabolites (Table 1; Figure S6) using
snap-frozen skin tissue of K14Cre;Nsdhlflx5/Y versus age-
matched Nsdhlflx5/flx5 mice. As expected (Cunningham et al.,
2015), an immediate substrate for NSDHL, 4b-carboxy,4a-
methyl-cholesta-8,27-dien-3b-ol, was elevated in the Nsdhl
null skin. FF-MAS accumulation was not detected; however,
interestingly, a number of ‘‘unconventional’’ C4-methylsterols
were also selectively detected in the context ofNsdhl conditional
ablation. These likely arise through the metabolic activity of the
downstream enzymes altering different carbon moieties of the
sterol precursor, e.g., by 24-dehydrocholesterol reductase
(DHCR24) eliminating the C24 double bond to produce
4a-methyl-5-cholesta-8-en-3b-ol, and by the C8-sterol isom-
erase (also known as EBP) to produce 4a-methyl-5-cholesta-
7-en-3b-ol and 4a-methyl-5-cholesta-7,24-dien-3b-ol (Fig-
ure S6). Levels of the DHCR24 substrate desmosterol, a known
LXR agonist (Yang et al., 2006), were increased >2.5-fold in
NSDHL-deficient skin samples, suggesting a possible competi-
tive inhibitory effect of some of these metabolites on DHCR24.
The abundance of multiple sterol species in NSDHL-deficient
skin tissues highlights the complex non-linear metabolic shifts
in the sterol metabolome induced by a single enzyme deficiency.
Convergent LXR and EGFR Signaling Regulates
Sensitivity to Erlotinib in Carcinomas
In many solid tumors, the de novo biosynthesis and uptake of
cholesterol are under tight regulation by the EGFR signaling
cascade (Guo et al., 2009, 2011). Conversely, we previously re-
ported aberrant EGFR signaling in cancer cells deficient in
NSDHL or SC4MOL (Astsaturov et al., 2010). We hypothesized
that combined inhibition of cholesterol metabolism and EGFR
pathway signaling could be synergistic in human carcinomas
because of signaling interactions mediated through LXRa. In
support of this idea, treatment of carcinoma cell lines A431
and SCC61 with epidermal growth factor (EGF) markedly
increased levels of LDLR and nuclear SREBP2, while treatment
with the EGFR inhibitor erlotinib reduced the expression of these
proteins (Figures 5A and 5B). In opposing action, treatment of
A431 and SCC61 cells with the LXR agonists 22-hydroxycholes-
terol and MAS suppressed LDLR and the nuclear fragment of
SREBP2 (Figure 5A).
The PI3K mutation-positive squamous carcinoma cell line
SCC61 (Seiwert et al., 2009) is refractory to EGFR inhibitors
in vitro. Silencing of LDLR with validated siRNA (Figure S5C) in
these cells markedly sensitized them to the effect of erlotinib
(Figure 5C). Given the established effect of LXR agonists on
depleting cancer cells of LDLR (Figure 5A), predicted to deplete
intracellular cholesterol (Figure 4E; Joseph et al., 2004), we
tested the combined treatment in erlotinib-refractory SCC25orts 12, 1927–1938, September 22, 2015 ª2015 The Authors 1933
Figure 5. EGFR and LXR Signaling Co-regulate Cholesterol Pathway Targets in Carcinoma
(A) Activation (EGF) or blockade of EGFR (erlotinib) regulates cholesterol metabolism via the expression of nuclear SREBP2 and LDLR in EGFR-positive A431 and
SCC61 cells. Conversely, LXR agonists FF-MAS and 22(R)-hydroxycholesterol reduce the expression of nuclear SREBP2 and LDLR.
(B) Summary of results quantified from (A) for SCC61 cells. Data are presented as mean ± SEM. *p = 0.02.
(C) Silencing of LDLR with siRNA sensitizes refractory SCC61 cells to erlotinib. Error bars represent SEM from three independent experiments; (1) p = 33 1011.
See also Figure S6.
(D) Addition of 3 mM FF-MAS or 3 mM 22(R)-hydroxycholesterol increased cytotoxicity of erlotinib in SCC25 cells. Data are presented as mean ± SEM of three
repeats; interaction, p = 0.003 (2) and p = 0.0002 (3), two-way ANOVA.
(E) Combined effects of erlotinib and 22(R)-hydroxycholesterol in SCC61 and SCC25 cells. Data are presented as mean ± SEM; interaction **p < 0.01.
(F) Enumeration of erlotinib and 22(R)-hydroxycholesterol interactions in vitro. Shown are averaged Chou-Talalay CI values ± SEM from three independent re-
peats. ED, effective dose; CI, combination index. See also Figure S6.
(G) Effects of fatostatin on SREBP1, SREBP2, and LDLR expression in A431 cells following treatment of serum-starved cells with EGF (20 ng/ml) and/or fatostatin
for 18 hr.
(H) Combined effects of erlotinib and fatostatin in A431 cells. Data are presented as mean ± SEM; interaction ***p < 103.
(I) Enumeration of erlotinib and fatostatin interactions in vitro as in (E).and SCC61 cells and in erlotinib-sensitive A431 cells. Both
22(R)-hydroxycholesterol and MAS sensitized the refractory
and sensitive carcinoma cell lines to erlotinib (combination index
[CI] < 1, Chou-Talalay method; Chou and Talalay, 1984) (Figures
5D–5F and S5D).
The expression of LDLR is, in part, stimulated by activated
SREBP1 (Guo et al., 2009). Therefore, inhibition of the nuclear
activated form of SREBP can potentially be exploited to deplete1934 Cell Reports 12, 1927–1938, September 22, 2015 ª2015 The Acarcinoma cells of LDLR. We tested an established SREBP in-
hibitor, fatostatin (Kamisuki et al., 2009), which potently reversed
the effect of EGF on the expression of nuclear fragments of
SREBP1 and SREBP2 and depleted LDLR in A431 cells in vitro
(Figure 5G). Combined treatment with fatostatin and erlotinib
produced synergistic cytotoxicity in the three squamous cell
carcinoma lines tested (CI < 1, Chou-Talalay method; Chou
and Talalay, 1984) (Figures 5H and 5I).uthors
DISCUSSION
This study identifies the interaction between NSDHL and LXR as
relevant to and targetable in the broad class of tumors with acti-
vated EGFR and RAS oncogenes. These results indicate that
therapeutic exploitation of NSDHL with potentially little toxicity
may be possible in adults despite earlier studies showing that
hypomorphic variants of SC4MOL (He et al., 2011) and NSDHL
(McLarren et al., 2010) cause developmental defects, while
alleles eliminating enzymatic activity cause arrest during early
embryonic development (Caldas et al., 2005). However, the con-
ditional knockout model of NSDHL employed in this study al-
lowed us to circumvent the severe pre- and perinatal effects of
NSDHL deficiency (Cunningham et al., 2015) and indicates that
loss of activity of the enzyme is tolerated in adult tissues, except
when these tissues are induced to malignant growth by onco-
genic transformation.
Earlier studies of NSDHL and SC4MOL deficiency left unre-
solved the question of whether the MAS accumulation was itself
responsible for observed biological effects, or whether these ef-
fects occurred as a consequence of changes in cholesterol
pools. Reflecting the complexity of biological systems, these
may be inseparable issues. An interesting aspect of this study,
which defines the nuclear sterol-binding receptor LXR as a crit-
ical effector activated by the accumulating sterol metabolites, is
that it now provides additional connections between NSDHL
activity and cholesterol levels, beyond the straightforward role
of C4-methylsterols as biosynthetic intermediates. Activated
LXR causes deregulation of cholesterol uptake by increasing
degradation of LDLR (Chawla et al., 2001; Guo et al., 2011)
and transcriptional induction of ATP-binding cassette (ABC)
transporters, known to negatively regulate the growth of he-
matopoietic (Bensinger et al., 2008; Yvan-Charvet et al., 2010)
and tumor cells (Guo et al., 2011). We demonstrated both in vivo
and in carcinoma cell lines that deficiency of SC4MOL or NSDHL
activates canonical LXR targets such as ABCA1 and ABCG1 and
represses LDLR, which regulate cellular release and uptake of
cholesterol, respectively. Our in vivo demonstration of a func-
tional NSDHL-LXR interaction mechanistically links C4-deme-
thylating enzymes to regulation of the growth of normal and
malignant cells. Further extending the interest of SC4MOL and
NSDHL function in oncogenesis, a recent paper (Santori et al.,
2015) used elegant biochemical experiments to identify a range
of ‘‘unusual’’ SC4MOL- and NSDHL-catabolized derivatives of
lanosterol that directly bind another nuclear receptor, the reti-
noid orphan receptor-g (RORg), to regulate maturation of Th17
lymphocytes, which play important roles in regulating tumor
growth. In our study, the sterol metabolites accumulating in vivo
in NSDHL-deficient cells are distinct from the reported RORg
ligands (Santori et al., 2015) (Table 1; Figure S6). Our demonstra-
tion of LXRa activation (Figure 4) in SC4MOL or NSDHL-deficient
cells will need further determination of the specific sterol species
bound to LXRa in the future.
In an earlier study, we showed that loss of NSDHL or SC4MOL
affected EGFR signaling in cancer cells (Sukhanova et al., 2013).
Here, we demonstrated synergy between activated LXR and
EGFR antagonists, thus pointing to the cholesterol pathway
as a critical target regulating the growth of human carcinomas.Cell RepThese results are interesting in the context of a recent study of
glioblastoma in which activated EGFR was shown to positively
regulate cholesterol uptake via LDLR and de novo cholesterol
synthesis (Guo et al., 2009, 2011). The fact that we observed
similar signaling interactions in KRAS-induced skin tumors ex-
tends the relevance of NSDHL-LXR signaling to the oncogenic
KRAS, a major cancer-causing gene currently not amenable to
drug therapy. Previous attempts to disrupt cholesterol homeo-
stasis in cancer with inhibitors of HMGCR (statins) have been
limited in efficacy due to extensive compensation for reduced
HMGCR activity by increased cholesterol uptake and de novo
synthesis (Clendening et al., 2010b; Dong et al., 2010). Arresting
the cholesterol pathway more distally at the level of the C4-de-
methylating enzymes has the potential to create an irrevocable
metabolic trap of combined blockade of cholesterol de novo
synthesis and LXR-dependent blockade of uptake through
LDLR and increased cholesterol efflux via ABCA1 and ABCG1.
Detailed analysis of each of these regulatory elements will likely
provide novel metabolic targets for cancer therapy.
EXPERIMENTAL PROCEDURES
Cell Lines, Compounds, and Antibodies
The A431 and FaDu cells were obtained from the American Type Culture
Collection andmaintained at the Fox Chase Cancer Center Cell Culture Facility
(Philadelphia, PA). The identity of the A431 cell line was confirmed by single
tandem repeat DNA profiling (Biosynthesis). The SCC61 and SCC25 cells
were kindly provided by Dr. Tanguy Y. Seiwert (University of Chicago, Chicago,
IL). All cell lines were mycoplasma free and maintained in DMEM supple-
mented with 10% v/v FBS and L-glutamine with 100 mg/ml penicillin/
streptomycin.
Pre-senescent MEFs were obtained from embryos at 13.5 days post-
coitum. We isolated Bpa1H/+ NSDHL null MEFs from GFP-positive NSDHL-ex-
pressing cells by flow sorting as described previously (Cunningham et al.,
2005). Cells were propagated in DMEM supplemented with 10% v/v FBS
and L-glutamine with 100 mg/ml penicillin/streptomycin and used at passages
4–6.
Erlotinib was obtained from the Fox Chase Cancer Center pharmacy,
FF-MAS (14-demethyl-14-dehydrolanosterol, cat. no. 700077) was purchased
from Avanti Polar Lipids; 22(R)-OH-cholesterol (H9384) and EGF (E9644) were
purchased from Sigma, compactin (sc-200853) and 2-hydroxypropyl-b-cyclo-
dextrin (sc-203461) were purchased fromSantaCruz, fatostatin (#341329) was
purchased from Calbiochem (EMD Millipore), and LDS was prepared
as described previously (Cunningham et al., 2005). For western blot and immu-
nohistochemistry experiments, we used the following antibodies: SREBP2
(ab30682), ABCA1 (ab7360), LDLR (ab30531), LXRa (ab41902), and LXRb
(ab106473) from Abcam; E-cadherin (#3195P), b-actin (#4967S), a-tubulin
(#3873S), and hemagglutinin-tag (#2367S) from Cell Signaling; NSDHL
(#15111-2-AP) from Proteintech Group; SREBP1 (sc-13551) from Santa
Cruz; and Ki67 (M7249) from Dako. Cholesterol in total cellular lysates was
determined by Amplex Red kit from Life Technologies.
qRT-PCR
For evaluation of target gene knockdown, cells were reverse transfected in six-
well plates, and total RNA was extracted using the RNeasy Mini Kit (QIAGEN)
48 hr after transfection. qRT-PCR reactions were conducted using TaqMan
probes and primers designed by the manufacturer using an ABI PRISM
7700 Detection System (Applied Biosystems). The results were analyzed
with the comparative Ct method to establish relative expression curves.
Mouse Models
Mice carrying the conditional knockout allele of Nsdhl (Cunningham et al.,
2015) were kindly provided by Dr. Gail Herman (The Research Institute atorts 12, 1927–1938, September 22, 2015 ª2015 The Authors 1935
Nationwide Children’s Hospital, Columbus, OH). These mice (official name:
Nsdhltm1.1Hrm, MGI:5581334, to be designated as Nsdhlflx5 here) are congenic
on a C57BL/6J background and were bred and kept under defined-flora path-
ogen-free conditions at the Association for Assessment and Accreditation
of Laboratory Animal Care (AAALAC)-approved animal facility of the Fox
Chase Cancer Center, Philadelphia, PA. The 4-week old K5CreERT;LSL-
KrasG12D;Nsdhlflx5 mice (Supplemental Experimental Procedures; Figure S1A)
at their first anagen (Nowak et al., 2008) were treated with tamoxifen (Sigma,
T5648) dissolved in corn oil (Sigma, C8267) at 40 mg/kg by oral gavage for 5
consecutive days. Mice were observed once weekly until first tumors formed.
Papilloma volumes were assessed twice a week as (length 3 width2)/2. Mice
were followed for at least 5 months or until average papilloma volumes ex-
ceeded 2,000 mm3, ulceration occurred, or animals showed distress or weight
loss more than 10%, per the local institutional animal care and use committee
guidelines. See also Supplemental Experimental Procedures.
Mouse Skin Tissue Collection and Immunohistochemistry
Skin biopsy specimens of adult animals were taken from the dorsal side of the
mouse under anesthesia with isoflurane and fixed in formalin for immunohisto-
chemistry (IHC). Newborn pups were sacrificed the same day after the birth by
CO2 inhalation, and skin samples were collected. Skin samples were cut into
three parts, where the first one was fixed in formalin for further IHC, RNA was
isolated from the second part using TRIzol (Life Technologies #15596-026) ac-
cording to the manufacturer’s protocol, and for western blot analysis, the third
part of tissue samplewashomogenized inRIPAbuffer (SantaCruz #24928)with
phosphatase and protease inhibitors (Thermo Scientific #1862495, #1861278)
on ice and cleared then by centrifugation. Small (1- to 2-mm) pieces from
mouse tails were used for genotyping (Supplemental Experimental Proce-
dures). For IHC, fixed skinwas embedded in paraffin and stainedwith indicated
antibodies diluted per the manufacturer’s instructions. Primary antibody bind-
ing was amplified using a Vectastain Elite ABC Kit (Vector Laboratories),
including biotinylated anti-rabbit secondary antibody. Antibody binding was
visualized using the Liquid DAB+ Substrate Chromogen System (Dako). Sam-
ples were counterstained for 1 min with hematoxylin. Immunostained slides
were scanned by an Aperio ScanScope CS scanner (Aperio), and selected re-
gions of interest were outlined manually. Expression levels of NSDHL, ABCA1,
LDLR, and Ki67, as well as skin thickness and sebaceous gland areas, were
measured using ImageScope software.
siRNA Transfections
The small interfering RNA (siRNA) targeting human sterol biosynthesis genes
and controls were obtained from QIAGEN (Supplemental Experimental Proce-
dures). Cells were transfected in triplicates with siRNA at 5 nmol/L concentra-
tions mixed with HiPerFect Transfection Reagent (QIAGEN) according to the
manufacturer’s reverse-transfection protocol.
In Vitro Viability Assays
For in vitro viability assays cells were plated in 96-well plates at 3,000 cells/
well and treated with drugs according to experimental conditions. The viability
was measured in 96 hr using CellTiter-Blue Viability Assay (Promega). The CI
was calculated from drug cytotoxicity or growth-inhibition curves. Corre-
sponding dilutions of ethanol and DMSO were added as vehicle and did not
affect the viability compared with that of untreated cells. To calculate the CI,
the computer software Calcusyn can be used, taking the entire shape of the
growth-inhibition curve into account to determine whether a combination is
synergistic, additive, or antagonistic.
LXRa Luciferase Reporter Assay
LXRa luciferase reporter assay (QIAGEN, Cignal Lenti Reporter Assay LXRa
Reporter Assay) was performed on primary MEF cell culture. Cells were plated
in 96-well plates at a concentration of 105 cells per well in 100 ml of the 10%
FBS/DMEM/25 mM HEPES/L-glutamine medium. In 24 hr, cells were infected
with lentivirus containing LXRa luciferase reporter construct (QIAGEN, 336851
CLS-7041L-1) with MOI = 10. To increase efficiency of infection, Polybrene
(Santa Cruz, sc-134220) was added at a final concentration of 8 mg/ml. 72 hr
after infection, cells were washed with PBS once and lysed in Passive Lysis
Buffer (Promega, E194A). Cell lysates were collected and the level of luciferase1936 Cell Reports 12, 1927–1938, September 22, 2015 ª2015 The Aexpression was evaluated by luminescence intensity in chemical reaction with
luciferase substrate (Promega, E151A).
Growth Curves of Primary MEFs
To determine the growth rate of primary MEFs, cells were propagated in 10%
FBS/DMEM/25 mMHEPES/L-glutamine medium with penicillin/streptomycin.
Early-passageMEFs (passage 4) were used for growth-curve analysis. 33 105
cells were cultured, and every 3 days, cells were harvested by trypsinization
and the number of cells was counted using a cell counter. 3 3 105 cells
were plated back again every time. The cumulative amount of cells was esti-
mated by multiplying the number of cells from the previous passage by the
ratio between the number of harvested and plated cells.
Senescence-Associated b-Galactosidase
SA-b-galactosidase activity was detected with the Senescence beta Galacto-
sidase Staining Kit (Cell Signaling #9860S) according to the manufacturer’s
protocol. Briefly, cells grown on glass coverslips were washed with PBS and
fixed in glutaraldehyde fixative solution for 15 min. Cells were then washed
again in PBS and stained in X-galactosidase solution overnight at 37C.
LXRa and LXRb Expression
LXRa and LXRb coding plasmid (DNASU Plasmid Repository, NR1H3 and
NR1H2 cDNA in pDONR221 vector, HsCD00296058 and HsCD00042671
clones, respectively) were cloned in pLEX-HA-MYC plasmid vector (Thermo
Scientific Open Biosystems,OHS4492) using theGateway cloning system (Invi-
trogen) according to the manufacturer’s protocol. Lentiviruses containing
NR1H3 or NR1H2 were then generated and expanded in HEK293T cells using
Trans-Lentiviral Packaging Mix (Thermo Scientific, TLP4606) and Express-In
Transfection Reagent (Thermo Scientific Open Biosystems, ETR4620-4623).
SCC61 cells were treated with obtained viruses, and infected clones were
selected then with 2 mg/ml puromycin (Santa Cruz #108071). For the control
cell line, pLEX-JRed-TurboGFP Control Vector (Thermo Scientific Open Bio-
systems, OHS4625) was packed in the same lentivirus (Trans-Lentiviral Pack-
agingMix, ThermoScientific,TLP4606)).SCC61cellswere treatedwithobtained
GFP-coding virus, and infected clones were selected with 2 mg/ml puromycin.
LXRa and LXRb overexpression was confirmed by western blot analysis of cell
lysates.
Sterol GC-MS
Sterol analysis was performed using ion-ratio GC-MS on an Agilent 6390N/
5973 GC-MS system as previously described (Kelley, 1995) with modifications
to the GC-MS method to include ions for additional intermediates in the
cholesterol biosynthetic pathway between lanosterol and cholesterol.
Statistical Analysis
For analysis of skin samples for biomarker expression, skin thickness and
sebaceous gland proliferation, papilloma growth, and the level of NSDHL
expression in tumors, we used the Wilcoxon test. Growth curves, unless
otherwise indicated, were modeled using linear regression with interactions
between exposure and concentration. All clustered or repeated data were ac-
counted for using linear regression with generalized estimating equations
(Liang and Zeger, 1986).
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